The current meta-analysis provides evidence that CML and GIST patients administered with imatinib carrying the homozygous variant of ABCG2 c.421C>A show higher imatinib Ctrough with respect to wild-type and heterozygous patients. Here, ABCG2 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.